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ABSTRACT
Previous prospective cohort studies have shown that serum levels of sex steroids and sex hormone-binding globulin (SHBG) associate
withnonvertebral fracture risk inmen. Thepredictive valueof sexhormones andSHBG for vertebral fracture risk specifically is, however,
less studied. Elderly men (aged 65 years) from Sweden and Hong Kong participating in the Osteoporotic Fractures in Men (MrOS)
study had baseline estradiol and testosterone analyzed by gas chromatography–mass spectrometry (GC-MS) and SHBG by
immunoradiometric assay (IRMA). Incident clinical vertebral fractures (n¼ 242 cases) were evaluated in 4324 men during an average
follow-upof 9.1 years. In a subsample of thesemen (n¼ 2256), spine X-rayswere obtained at baseline andafter an average follow-upof
4.3 years to identify incident radiographic vertebral fractures (n¼ 157 cases). The likelihood of incident clinical and radiographic
vertebral fractures was estimated by Cox proportional hazards models and logistic regression models, respectively. Neither serum
estradiol (hazard ratio [HR] per SD increase¼ 0.93, 95% confidence interval [CI] 0.80–1.08) nor testosterone (1.05, 0.91–1.21) predicted
incident clinical vertebral fractures in age-adjusted models in the combined data set. High serum SHBG, however, associated with
increased clinical vertebral fracture risk (1.24, 1.12–1.37). This association remained significant after further adjustment for FRAXwith or
without bonemineral density (BMD). SHBG also associatedwith increased incident radiographic vertebral fracture risk (combined data
set; odds ratio [OR] per SD increase¼ 1.23, 95% CI 1.05–1.44). This association remained significant after adjustment for FRAX with or
withoutBMD. In conclusion, highSHBGpredicts incident clinical and radiographic vertebral fractures inelderlymenandaddsmoderate
information beyond FRAX with BMD for vertebral fracture risk prediction. © 2015 The Authors. Journal of Bone and Mineral Research
published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
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Introduction
Osteoporosis and osteoporosis-related fractures in menaccount for considerable disease burden and costs for
society. Both androgens and estrogens affect bone health in
men, and previous studies have shown that serum sex steroid
levels associate with nonvertebral fracture risk.(1) In particular,
low serum estradiol and testosterone and high sex hormone-
binding globulin (SHBG) levels result in increased likelihood of
all and nonvertebral fractures.(2–8)
The predictive value of sex steroids and SHBG specifically for
vertebral fracture risk in men is, however, less studied. Both total
and bioavailable estradiol associated with increased risk of
incident radiographic vertebral fractures in the Rancho Bernardo
Study, including 352 older men with 28 fracture cases over an
8-year follow-up.(9) Yet, the Rotterdam Study, evaluating 178
older men with 45 radiographic vertebral fractures during an
average follow-up of 6.5 years, found no significant associations
of sex steroids or SHBG with fracture risk.(10) Regarding incident
clinical vertebral fractures, Meier and colleagues reported high
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SHBG to be associated with increased fracture risk in the Dubbo
Osteoporosis Epidemiology Study in which 55 clinical vertebral
fractures were reported in 609men during amedian follow-up of
5.8 years.(5) Taken together, theavailable studies investigating the
association between sex steroids and future vertebral fracture risk
are scarce, not well powered, and include a limited number of
incident fractures. We, therefore, investigated the predictive
value of serum sex steroids and SHBG for incident vertebral
fracture risk inmoredetail in two large,well-characterized cohorts
of older men with high fracture incidence in Sweden and Hong
Kong during an average follow-up of 9.1 years.
Materials and Methods
Study sample
The Osteoporotic Fractures in Men (MrOS) study is amulticenter,
prospective study including older men in Sweden (n¼ 3014),
Hong Kong (n¼ 2000), and the United States (n¼ 5994). In this
study, associations between serum sex steroids, SHBG, and
incident vertebral fractures were investigated in the cohorts
from Sweden and Hong Kong (Table 1). The MrOS Sweden
cohort consists of three subcohorts from three different Swedish
cities (n¼ 1005 in Malm€o, n¼ 1010 in Gothenburg, and n¼ 999
in Uppsala). Study subjects (men aged 69 to 81 years) were
randomly selected using national population registers, con-
tacted, and asked to participate. To be eligible for the study, the
subjects had to be able to walk without assistance, provide self-
reported data, and sign an informed consent.(11) The study was
approved by the ethics committees at the Universities of
Gothenburg, Lund, and Uppsala. Informed consent was
obtained from all study participants. The MrOS Hong Kong
cohort includes 2000 Chinese men aged 65 years or older who
were recruited by advertisements placed in housing estates and
community centers for elderly people. All subjects had to be
community dwelling, able to walk without assistance, and not
have bilateral hip replacement. Stratified sampling was
adopted to achieve approximately 33% of the participants in
each of the three age groups: 65–69, 70–74, and 75 years.(12)
The study protocol was approved by the Chinese University of
Hong Kong ethics committee, and written informed consent
was obtained from all subjects. Participants with surgical or







Age (years) 75.4 3.2 72.5 5.0 74.4 4.1
Height (cm) 174.7 6.6 163.0 5.7 170.7 8.4
Weight (kg) 80.6 12.1 62.1 9.4 74.3 14.3
BMI (kg/m2) 26.4 3.6 23.3 3.1 25.3 3.7
Serum sex steroids
Estradiol (pg/mL)a 21.2 7.5 24.6 14.3 22.4 10.7
Bioavailable E2 (pg/mL) 13.2 5.0 15.1 9.6 13.9 7.1
Testosterone (ng/dL)a 457 176 548 204 490 192
Bioavailable testosterone (ng/dL) 180 70 207 59 190 67
SHBG (nmol/L) 47.2 21.8 51.2 20.4 48.5 21.4
Validated vertebral fractures (n, %)
Incident clinical vertebral fractures 221/2847 (7.8) 21/1477 (1.4) 242/4324 (5.6)
Incident radiographic vertebral fractures 91/1108 (8.2) 66/1148 (5.7) 157/2256 (7.0)
Prevalent radiographic vertebral fractures 149/1108 (13.4) 43/1148 (3.7) 192/2256 (8.5)
FRAX without BMD (%) 11.0 4.4 6.9 2.8 9.6 4.4
FRAX with BMD (%) 9.8 5.5 6.7 3.2 8.7 5.1
Lumbar spine BMD (g/cm2) 1.14 0.20 0.95 0.18 1.08 0.22
Calcium intake (mg/d) 898 433 628 298 805 413
Physical activity (km/d) 4.0 3.2 1.4 1.5 3.1 3.0
Grip strength (kg) 39.9 7.4 31.0 6.6 36.8 8.3
Corticosteroid use (n, %) 52 (1.8) 19 (1.3) 71 (1.6)
Smoking (n, %) 241 (8.5) 175 (11.8) 416 (9.6)
Alcohol 3 units per day (n, %) 62 (2.2) 10 (0.7) 72 (1.7)
Falls during past 12 months (n, %) 466 (16.4) 224 (15.2) 690 (16.0)
Fractures after the age of 50 years (n, %) 186 (6.5) 101 (6.8) 287 (6.6)
Major prevalent diseases (n, %)
Cancer 380 (13.4) 60 (4.1) 440 (10.2)
COPD 238 (8.4) 179 (12.1) 417 (9.7)
Diabetes 269 (9.5) 225 (15.2) 494 (11.4)
Stroke 180 (6.3) 84 (5.7) 264 (6.1)
Rheumatoid arthritis 41 (1.4) 17 (1.2) 58 (1.3)
Data are presented for those subjects with fracture information and serum SHBG levels available, and excluding those with surgical or chemical
castration and androgen or anti-androgen treatment. Values are given as mean SD or n (%). FRAX is the country-specific calculated estimate of the 10-
year risk of a major osteoporotic fracture.
COPD¼ chronic obstructive pulmonary disease.
aSerum testosterone levels in healthy adult males vary from 315 to 1000 ng/dL (11 to 35 nmol/L), whereas estradiol concentrations are around 20 to
30 pg/mL (70 to 110 pmol/L).(30)
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chemical castration, and androgen or anti-androgen treatment
were excluded from the analyses.
Assessment of covariates
In both the MrOS Sweden and Hong Kong cohorts, we used a
standardized questionnaire to gather information about self-
reported previous fractures after age 50 years, falls (yes/no)
during the last 12 months preceding the baseline visit, amount
of physical activity, nutritional intake, smoking, alcohol use,
prevalent major diseases (diabetes, stroke, chronic obstructive
pulmonary disease, rheumatoid arthritis, and cancer), and use of
glucocorticoids. Physical activity was the subject’s average total
daily walking distance, including both walking as a means of
exercise and leisure and as a means of outdoor transportation in
activities of daily life. Calcium intake was estimated from dairy
product intake. Alcohol use was expressed as three or more
glasses of alcohol-containing drinks per day, calculated from the
reported frequency and amount of alcohol use. Grip strength
was analyzed using a dynamometer; two measurements were
taken on each side and the average of right and left was used in
the analyses. Standard equipment was used to measure height
and weight. Body mass index (BMI) was calculated by dividing
the weight in kg by the height in meter squared.
Areal BMD (aBMD, g/cm2) of the femoral neck and lumbar
spine (L1 to L4) was assessed at baseline using the Lunar Prodigy
dual-energy X-ray absorptiometry (DXA; GE Lunar Corp.,
Madison, WI, USA) in the Uppsala and Malm€o cohorts and the
Hologic QDR 4500/ A-Delphi (Hologic, Waltham, MA, USA) in
theGothenburg cohort. The coefficients of variation (CVs) for the
aBMDmeasurements ranged from0.5% to 3%depending on the
application. To be able to use DXA measurements performed
with equipment from two different manufacturers, a standard-
ized BMD (sBMD) was calculated, as described previously.(11) In
MrOS Hong Kong, aBMD at the femoral neck and lumbar spine
was measured using the Hologic QDR 4500/ A-Delphi with CVs
<1%.
The country-specific FRAX tool was used to assess a subject’s
calculated 10-year probability of a major osteoporotic fracture
(clinical spine, distal radius, proximal humerus, or hip) (www.
shef.ac.uk/FRAX/). It integrates the fracture risks associated with
clinical risk factors as well as femoral neck BMD.(13)
Assessment of vertebral fractures
Incident clinical vertebral fractures
In MrOS Sweden, central registers covering all Swedish citizens
were used to identify the subjects, and at the time of fracture
evaluation, computerized X-ray archives were searched for new
vertebral fractures occurring after the baseline visit.(4) In MrOS
Hong Kong, fractures were ascertained by the Hong Kong
Hospital Authority electronic database, which included com-
puterized X-ray archives. In addition, the subjects were
contacted at 4-monthly intervals for fracture incidence during
the first 4 years of follow-up.(8) All fractures were verified by
X-ray. The mean follow-up time for fractures was 8.6 years in
Sweden and 9.9 years in Hong Kong.
Prevalent and incident radiographic vertebral fractures
In Sweden, X-rays of the lateral thoracic and lumbar spine were
obtained both at baseline and after an average follow-up of
4.7 years in 1156 subjects. The radiographs were evaluated for
vertebral fractures at both time points by an expert radiologist
(IR-J) using a modified semiquantitative method developed
by Genant and colleagues.(14,15) In Hong Kong, lateral thoracic
and lumbar spine radiographs were obtained at baseline
and after 4 years in 1566 participants. The films were assessed
by two radiologists using Genant’s semiquantitative scoring
system.(14,16)
Serum analyses
A validated gas chromatography–tandem mass spectrometry
system(17–19) was used to analyze serum testosterone (limit of
detection 0.05 ng/mL, intra-assay CV 2.9%, interassay CV 3.4%)
and estradiol (limit of detection 2.00 pg/mL, intra-assay CV 1.5%,
interassay CV 2.7%) in the samples fromMrOS Sweden and Hong
Kong. Serum was also assayed for SHBG using immunoradio-
metric assay (IRMA) (Spectria, Orion Diagnostica, Espoo, Finland)
with an intra-assay CV of less than 5.5% and an interassay CV of
less than 6.9%. More than half of the subjects in Sweden (1928/
2847, 67.7%) hadmorning samples (drawn before 10.00 am); the
remaining were drawn around noon. All Hong Kong samples
were fasting samples. Bioavailable estradiol and testosterone
levels were calculated using law-of-mass-action equations using
association constants estimated from a systematic review of
published binding studies and an iterative numeric method.(20)
Statistical analyses
In predefined analyses, the associations between serum levels of
sex steroids and SHBG and incident clinical vertebral fractures
were analyzed using Cox proportional hazards models. Logistic
regression models were used to examine the associations
between sex steroids and SHBG and incident radiographic
vertebral fractures. We show the effect estimates with the 95%
confidence intervals (CIs) within parentheses for a 1-SD increase
(Z-score) in serum sex steroid or SHBG levels. All estimates were
adjusted for time of serum sampling, cohort, and MrOS Sweden
site. Further adjustments were made for body mass index (BMI),
a multivariate model (calcium intake, smoking, alcohol use, falls,
grip strength, physical activity, fractures after the age of 50
years/prevalent radiographic vertebral fractures, prevalent
diseases [diabetes, cancer, stroke, COPD, rheumatoid arthritis],
and glucocorticoid use), and lumber spine BMD to assess the
independent effects of serum SHBG on vertebral fracture
outcome. The models used to estimate the associations
between serum testosterone, estradiol, and SHBG, entered as
continuous variables, and vertebral fracture incidence were
performed in both cohorts separately as well as in the combined
cohort, for which the analyses were adjusted for the individual
cohorts. SHBG was also examined as quartiles and further as a
dichotomous variable comparing quartile 4 to quartiles 1 to 3.
The association between serum levels of SHBG and testosterone
was examined using partial correlation, controlling for time of
serum sampling, cohort, and MrOS Sweden site.
Fracture discrimination was determined using C-statistics,
where the statistical significance of change in the area under the
ROC curve (AUC) between models was tested with the roc.test
function in R using settings according to DeLong and
colleagues.(21) Fracture reclassification analyses were performed
by calculating the integrated discrimination improvement (IDI)
and net reclassification improvement (NRI) according to Pencina
and colleagues.(22) The improvements in risk prediction by
SHBG as a continuous parameter were evaluated over baseline
models, including age or FRAX estimates with or without BMD.
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To identify the proportion of subjects correctly reclassified by
adding SHBG levels as extra predictors, the incremental
discriminative ability of the SHBG levels compared with age
or FRAX estimates (both with andwithout BMD) was assessed by
using category-free NRI and IDI.
All statistical analyses were performed using SPSS software
(version 21.0; Chicago, IL, USA).
Results
Characteristics of the study subjects
The baseline characteristics of the study subjects in the MrOS
Sweden and Hong Kong cohorts as well as in the combined
cohort are shown in Table 1. Data are presented for those
subjects with fracture information and serum SHBG levels
available, and excluding those with surgical or chemical
castration and androgen or antiandrogen treatment. At
baseline, the mean age of the men in the combined cohort
(n¼ 4324) was 74.4 years. During an average follow-up time of
9.1 years, a total of 242 men had at least one validated incident
clinical vertebral fracture (rate of 6.2 per 1000 person-years).
In a combined subsample of 2256 men who had a spine X-ray
both at baseline and after an average follow-up of 4.3 years,
8.5% had at least one prevalent radiographic vertebral fracture,
whereas 157 incident radiographic vertebral fractures were
identified (Table 1).
Serum SHBG as a predictor of incident clinical vertebral
fracture risk
Age-adjusted Cox proportional hazards models demonstrated
that high serum SHBG associated with increased clinical
vertebral fracture risk in the combined data set when analyzed
as a continuous variable (24% increased risk per SD increase in
SHBG, Table 2). Significant associations between SHBG and
clinical vertebral fracture risk were also observed in the
individual cohorts. In contrast, neither serum estradiol nor
testosterone predicted fracture risk in corresponding analyses
(Table 2). Low levels of bioavailable estradiol, but not
bioavailable testosterone, associated significantly with in-
creased clinical vertebral fracture risk. However, when both
serum SHBG and bioavailable estradiol were included in the
same model, only SHBG independently predicted the risk of
incident clinical vertebral fractures (hazard ratio [HR] per SD
increase¼ 1.24, 95% confidence interval [CI] 1.12–1.37). Further
exploratory analyses showed that when assigning men in
quartile 1 of SHBG levels as a referent, clinical vertebral fracture
risk was increased in men within the highest quartile of SHBG
levels, whereas the fracture risk in the individual quartiles 2 and 3
was similar to that of quartile 1 (Supplemental Table S1).
Comparedwithmenwithin the pooled quartiles 1 to 3,menwith
SHBG levels within quartile 4 were at significantly greater risk
(52%) of a clinical vertebral fracture.
Serum SHBG as an independent predictor of incident
clinical vertebral fracture risk
Multivariate adjustment for traditional risk factors for fracture
(BMI, calcium intake, smoking, alcohol use, falls, grip strength,
physical activity, fractures after the age of 50 years, prevalent
diseases [diabetes, cancer, stroke, COPD, rheumatoid arthritis],
and glucocorticoid use) did not substantially change the
association between serum SHBG and clinical vertebral
fractures in the combined cohort or the individual cohorts
(Table 3). Moreover, the association remained significant after
adjustment for FRAXwithout BMD and FRAXwith BMD (Table 3).
To address whether the association between serum SHBG and
clinical vertebral fracture risk is mediated by BMD, further
adjustments were made. After inclusion of lumber spine BMD in
the model, the association between serum SHBG and long-
term risk of clinical vertebral fracture was slightly attenuated
but remained significant (HR per SD increase¼ 1.14, 95%
CI 1.03–1.27).
Table 2. Serum Sex Steroids and the Risk of Incident Clinical Vertebral Fractures
MrOS Sweden MrOS Hong Kong Combined
Estradiol (per SD increase) 0.96 (0.82–1.12) 0.45 (0.19–1.04) 0.93 (0.80–1.08)
Bioavailable estradiol (per SD increase) 0.87 (0.74–1.03) 0.22 (0.09–0.55) 0.84 (0.71–0.98)
Testosterone (per SD increase) 1.03 (0.89–1.20) 1.19 (0.80–1.77) 1.05 (0.91–1.21)
Bioavailable testosterone (per SD increase) 0.88 (0.74–1.04) 0.71 (0.46–1.10) 0.85 (0.73–1.00)
SHBG (per SD increase) 1.21 (1.09–1.34) 1.68 (1.21–2.35) 1.24 (1.12–1.37)
Age-adjusted hazard ratios are given with 95% CIs within parentheses. All models are also adjusted for time of serum sampling, cohort, and MrOS
Sweden site when applicable.
Table 3. Serum SHBG as an Independent Predictor of Incident Clinical Vertebral Fracture Risk
MrOS Sweden MrOS Hong Kong Combined
SHBG (per SD increase)
A. Base model 1.21 (1.09–1.34) 1.75 (1.27–2.43) 1.21 (1.09–1.34)
B. Multivariate model 1.20 (1.07–1.34) 1.77 (1.29–2.44) 1.22 (1.10–1.35)
C. FRAX without BMD 1.23 (1.11–1.37) 1.60 (1.14–2.23) 1.26 (1.14–1.39)
D. FRAX with BMD 1.22 (1.09–1.35) 1.59 (1.13–2.25) 1.25 (1.13–1.38)
Cox proportional hazards regressionmodels for SHBG in (A) a basemodel (adjusted for age and BMI); (B) amultivariatemodel (age, BMI, calcium intake,
smoking, alcohol use, falls, grip strength, physical activity, fractures after the age of 50 years, prevalent diseases [diabetes, cancer, stroke, COPD,
rheumatoid arthritis], and glucocorticoid use); (C) a model including FRAX without BMD; and (D) a model including FRAX with BMD. All models are
adjusted for time of serum sampling, cohort, and MrOS Sweden site when applicable. Hazard ratios are given with 95% CIs within parentheses. FRAX is
the country-specific calculated estimate of the 10-year risk of a major osteoporotic fracture.
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Serum SHBG improves clinical vertebral fracture risk
reclassification
Serum SHBG slightly improved clinical vertebral fracture risk
discrimination (AUC) from a model adjusted for age (p< 0.05)
when evaluated in the MrOS Sweden cohort. No significant
improvements in discrimination with SHBG were observed from
models adjusted for FRAX without BMD or FRAX with BMD
(Table 4). When evaluated with the more sensitive IDI and NRI,
SHBG significantly but modestly improved clinical vertebral
fracture reclassification models of age, of FRAX without BMD,
and of FRAX with BMD.
Serum SHBG as a predictor of incident radiographic
vertebral fracture risk
Age-adjusted logistic regression models in the MrOS Hong
Kong subsample showed that high serum SHBG associated
with an increased risk of radiographic vertebral fractures. The
same tendency was present in the MrOS Sweden subsample,
but this association was not significant (Supplemental
Table S2). In the combined subsample, high serum SHBG
significantly associated with increased radiographic vertebral
fracture risk (23% increased risk per SD increase in SHBG,
Table 5). Serum levels of estradiol, bioavailable estradiol, and
bioavailable testosterone were not significantly associated
with radiographic vertebral fracture risk, but (somewhat
surprisingly) subjects with high testosterone were at increased
risk of fracture. However, when both SHBG and testosterone
were tested in the same model, only SHBG independently
predicted the risk of incident radiographic vertebral fractures
(odds ratio [OR] per SD increase¼ 1.22, 95% CI 1.04–1.43).
Serum SHBG as an independent predictor of incident
radiographic vertebral fracture risk
As expected, prevalent radiographic vertebral fractures at
baseline strongly predicted the risk of incident radiographic
vertebral fractures (OR¼ 5.21, 95% CI 3.62–7.50). Multivariate
adjustment for traditional risk factors for fracture including this
risk factor (BMI, calcium intake, smoking, alcohol use, falls, grip
strength, physical activity, prevalent radiographic vertebral
fractures, prevalent diseases [diabetes, cancer, stroke, COPD,
rheumatoid arthritis], and glucocorticoid use) did not substan-
tially change the association between serum SHBG and
radiographic vertebral fractures (Table 6). Furthermore, this
association remained significant after adjustment for FRAX
without BMD or FRAX with BMD.
Discussion
In this large, prospective study of Swedish and Chinese men,
subjects with the highest SHBG levels had higher risk of incident
radiographic and clinical vertebral fractures. The predictive role
of SHBG for vertebral fracture risk was partly independent of
BMD and largely independent of other known risk factors for
fracture.
The association between sex steroids and SHBG and non-
vertebral fracture risk in men is well studied (for review see
Table 4. Serum SHBG and Incident Clinical Vertebral Fracture Risk Discrimination and Reclassification in MrOS Sweden
Discrimination Reclassification IDI Reclassification NRI
C index IDI Event Nonevent NRI Event Nonevent
Age 0.56
þ SHBG 0.59 0.005 0.005 0.000 0.200 –0.078 0.278
FRAX without BMD 0.57
þ SHBG 0.59 0.005 0.005 0.000 0.194 –0.088 0.282
FRAX with BMD 0.61
þ SHBG 0.62 0.004 0.004 0.000 0.178 –0.094 0.272
IDI¼ integrated discriminative improvement; NRI¼net reclassification improvement.
Incident clinical vertebral fracture risk discrimination and reclassification for different models (age, FRAX without BMD, and FRAX with BMD) after
addition of serum SHBG. FRAX is the country-specific calculated estimate of the 10-year risk of a major osteoporotic fracture. Bold indicates p< 0.05.
Table 5. Serum Sex Steroids and the Risk of Incident
Radiographic Vertebral Fractures
OR (95% CI)
Estradiol (per SD increase) 1.05 (0.88–1.25)
Bioavailable estradiol (per SD increase) 0.97 (0.79–1.19)
Testosterone (per SD increase) 1.22 (1.03–1.44)
Bioavailable testosterone (per SD increase) 1.06 (0.88–1.27)
SHBG (per SD increase) 1.23 (1.05–1.44)
Age-adjusted odds ratios (ORs) are given with 95% CIs within
parentheses for the combined cohort. All models are also adjusted for
time of serum sampling, cohort, and MrOS Sweden site.
Table 6. Serum SHBG as an Independent Predictor of Incident
Radiographic Vertebral Fracture Risk
OR (95% CI)
SHBG (per SD increase)
A. Base model 1.22 (1.05–1.43)
B. Multivariate model 1.22 (1.03–1.45)
C. FRAX without BMD 1.24 (1.06–1.44)
D. FRAX with BMD 1.23 (1.05–1.43)
Binary logistic regression models in the combined cohort for SHBG in
(A) a base model (adjusted for age and BMI); (B) a multivariate model
(age, BMI, calcium intake, smoking, alcohol use, falls, grip strength,
physical activity, prevalent radiographic vertebral fractures, prevalent
diseases [diabetes, cancer, stroke, COPD, rheumatoid arthritis], and
glucocorticoid use); (C) a model including FRAX without BMD; and
(D) a model including FRAX with BMD. All models are adjusted for time
of serum sampling, cohort, and MrOS Sweden site. Odds ratios (ORs) are
given with 95% CIs within parentheses. FRAX is the country-specific
calculated estimate of the 10-year risk of a major osteoporotic fracture.
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Vanderschueren and colleagues(1)). Yet, the role of sex steroids
and SHBG for vertebral fracture risk particularly is not thoroughly
investigated in men, with the few available studies being small
and having a limited number of incident fractures. In the present
study with the largest number of subjects and highest fracture
incidence to date, we show that high levels of SHBG associated
with increased risk of clinical vertebral fractures in older men.
When analyzed as quartiles, those subjects within the highest
quartile of SHBG were at highest risk of fracture. Our study
confirms a previous report from the Dubbo Osteoporosis
Epidemiology Study showing a significant independent associ-
ation between serum SHBG levels and an increased risk of
symptomatic vertebral fractures. In a multivariate analysis
including testosterone, high serum SHBG levels independently
predicted a 55% increased risk per SD increase in SHBG.(5) The
association in our study was not altered after adjustment for
multiple known risk factors for fracture such as smoking, use of
alcohol, physical performance, previous fractures, previous falls,
and several chronic conditions.
The association of SHBG with incident clinical vertebral
fractures was partially attenuated after adjustment for lumbar
spine BMD, suggesting that almost half of the impact of SHBG is
mediated via effects on bone density. SHBG may affect fracture
risk indirectly by binding testosterone and estradiol and hereby
reducing the free and bioavailable levels of sex steroids. It has
also been speculated that SHBGmay directly amplify sex steroid
intracellular signaling via a putative membrane receptor and
SHBG-sex steroid interactions.(23) Alternatively, SHBG could be a
marker for nonskeletal determinants of fracture risk. SHBG levels
have been associated with frailty,(24) but in our study,
adjustment for grip strength, physical activity, and previous
falls did not affect the association between SHBG and vertebral
fracture risk.
We also tested the predictive value of serum SHBG levels for
fracture risk discrimination. When tested in Cox models, the
association between SHBG and clinical vertebral fractures
remained unchanged after addition of probability estimates
from the risk assessment tool FRAX and that with or without
including BMD. Furthermore, SHBG slightly improved fracture
risk reclassification when added to base models of FRAX with or
without BMD. This suggests that serum SHBG levels are a risk
marker for clinical vertebral fractures, by adding information
beyond risk estimates from the FRAX tool, with or without BMD.
Serum estradiol and testosterone did not associate indepen-
dently with clinical vertebral fracture risk in our study. Low
bioavailable estradiol levels associated with increased risk of
clinical vertebral fractures, but this association was lost after
adjusting for SHBG. It is plausible that different sex steroid-
related fracture risk determinants exist for bone sites containing
either predominantly trabecular (vertebrae) or cortical bone
(appendicular sites and hip). Our findings indicate that SHBG
independently predicts clinical vertebral fracture risk, whereas
previous evidence from us and others implicates serum estradiol
and to a lesser extent serum testosterone in risk prediction of
nonvertebral fractures.(1) The latter is supported by studies
showing that the threshold estradiol level for maintaining bone
mass is more apparent at cortical than trabecular sites(25) and
that estradiol levels are related to cortical porosity in men.(26)
The predictive role of sex steroids and SHBG for incident
radiographic vertebral fractures has not yet been studied inwell-
powered cohorts. In our large cohort of older men, we found
that high serum SHBG associated with increased fracture risk,
similarly as for incident clinical vertebral fractures. Notably,
SHBG associated with incident radiographic vertebral fractures
even after adjustment for prevalent radiographic vertebral
fractures at baseline. This makes it unlikely that our results are
based only on the increased fracture risk in subjects with poor
general health status. This association between SHBG and
radiographic vertebral fractures also remained significant after
addition of probability estimates from the risk assessment tool
FRAX and that with or without including BMD. This suggests that
serum SHBG levels are a risk marker not only for clinical but also
for radiographic vertebral fractures.
Serum estradiol levels (total or bioavailable) did not associate
with radiographic vertebral fracture risk in our older men. This is
in agreement with data from the Rotterdam Study(10) but
contradicts findings from the Rancho Bernardo Study in which
men in the lowest quintile of total or bioavailable estradiol had
significantly higher odds for vertebral fracture than those in the
highest quintile.(9) High levels of testosterone associated with
increased risk for incident radiographic vertebral fractures.
However, when both SHBG and testosterone were tested in the
same model, only SHBG independently predicted the risk of
incident radiographic vertebral fractures in our study. The
association for testosterone can be explained by the fact that
serum levels of testosterone and SHBG are highly correlated
(r¼ 0.57, p< 0.001), so when serum SHBG levels are high, the
total testosterone concentrations are increased as well, which
could explain the observed association.
Our study has a number of strengths. It is population based
and consists of the largest data set to date with a high fracture
incidence and well-characterized fracture phenotypes. More-
over, the findings are largely consistent among older white and
Asian men. However, this study also has limitations. The results
are based on single serum measurements and may thus
underestimate true associations. The inclusion of some non-
morning samples might have contributed to increased variabili-
ty, but this was adjusted for in all the analyses by time of
sampling. In addition, the bioavailable sex steroids levels were
calculated and not, as preferable, directly measured by
equilibrium dialysis-liquid chromatography-tandem mass spec-
trometry. A limitation of all association studies analyzing
circulating sex steroid levels is that a valid estimate of the local
levels of testosterone and estradiol in target tissues such as bone
is lacking. It is plausible that serum SHBG regulates the local
levels of testosterone, estradiol, or the balance between
estradiol and testosterone in bone and, thereby, influences
sex steroid action in bone. Importantly, these possible effects of
circulating SHBG on bioavailable sex steroid levels locally in
bonemight differ substantially from its effect on circulating total
levels of sex steroids. Also, the FRAX tool provides a 10-year
probability of hip fracture and major osteoporotic fracture
(including vertebral fracture) but no specific clinical vertebral
fracture risk calculation, making FRAX less optimal as a covariate
for the evaluation of vertebral fracture risk in the present study.
Still, although FRAX is not developed for estimating vertebral
fracture risk, other studies also used FRAX probability estimates
to assess vertebral fracture risk.(27–29) Finally, we have tried to
adequately adjust for confounders in all our analyses but cannot
rule out residual confounding.
In conclusion, high SHBG associated with increased clinical
and radiographic vertebral fracture risk in elderly men and adds
moderate information beyond FRAX with BMD for vertebral
fracture risk prediction.
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